This study is testing a drug called DR-01 in adults with Alopecia Areata (a condition causing hair loss) or Vitiligo (a condition causing skin discoloration). The main goals are to see how safe DR-01 is, how well people tolerate it, and if it shows any positive effects on hair regrowth or skin repigmentation. Researchers will also look at how the body processes DR-01. You may be able to join if you are at least 18 years old. The study plans to enroll 81 participants, but its current status is unclear.

Study design

This is an open-label, randomized study, meaning you and your doctors will know if you are receiving DR-01. It is a Phase 1b study and plans to include 81 participants.

What's involved

DR-01 will be given through an IV infusion. The study will measure safety and tolerability for up to 12 months, and changes in your condition at week 24.

Compensation

Not stated in the trial record.

Follow-up

Your safety and tolerability will be monitored for up to 12 months after starting the study. Changes in your condition will be measured at week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.